Lyell Immunopharma appoints Lynn Seely as President and CEO, succeeding Elizabeth Homans

Lyell Immunopharma, Inc.

Elizabeth Homans steps down as CEO effective Dec 15, 2022; will remain as consultant through June 2024.
Homans receives $900k base salary severance (18 months), $360k target bonus, continued option vesting, COBRA.
Lynn Seely appointed President and CEO; annual base salary $650k, target bonus 60%, and option for 7.5M shares.
Seely previously CEO of Myovant Sciences and CMO of Medivation; joined Lyell Board in May 2021.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Elizabeth Homans

Chief Executive Officer

LYEL · Lyell Immunopharma, Inc.

Effective: 2022-12-15
Successor: Lynn Seely
Filed: December 16, 2022, 6:59 PM ET

On December 15, 2022, Lyell Immunopharma, Inc. (the “Company”) announced that Ms. Elizabeth Homans would step down from her position as Chief Executive Officer and as a member of the Board of Directors (the “Board”) of the Company effective December 15, 2022

Appointed

Lynn Seely

President and Chief Executive Officer

LYEL · Lyell Immunopharma, Inc.

Effective: 2022-12-15
Filed: December 16, 2022, 6:59 PM ET

On December 14, 2022, Dr. Seely entered into an offer of employment with the Company (the “Seely Offer Letter”), pursuant to which she commenced her role as the Company’s President and Chief Executive Officer on December 15, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Elizabeth Homans resigned as Chief Executive Officer at Lyell Immunopharma, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On December 15, 2022, Lyell Immunopharma, Inc. (the “Company”) announced that Ms. Elizabeth Homans would step down from her position as Chief Executive Officer and as a member of the Board of Directors (the “Board”) of the Company effective December 15, 2022

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Lynn Seely was appointed as President and Chief Executive Officer at Lyell Immunopharma, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On December 14, 2022, Dr. Seely entered into an offer of employment with the Company (the “Seely Offer Letter”), pursuant to which she commenced her role as the Company’s President and Chief Executive Officer on December 15, 2022

View on SEC.gov

Lyell Immunopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-307296

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.